Our finding further strengthens the importance of VEGF and angiogenesis in progression of RCC and supports the efficacy of angiogenesis inhibitors in all RCC, including non-clear cell subtypes [65]. The gene discussed is VEGFA; the disease is renal cell carcinoma.